AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23806929 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital animation
Number of subjects: 32
Study 23806929 — intervention group
Group type: COMPARATOR
Intervention: Textbook
Number of subjects: 32
Study 21482337 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple aspiration
Number of subjects: 400
Study 21482337 — intervention group
Group type: COMPARATOR
Intervention: Chest tube drainage
Number of subjects: 400
Study 18639301 — intervention group
Group type: EXPERIMENTAL
Intervention: Air charged catheter
Number of subjects: 64
Study 18639301 — intervention group
Group type: COMPARATOR
Intervention: Microtip catheter
Number of subjects: 64
Study 16504165 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailor-made program addressing biopsychosocial factors
Number of subjects: 126
Study 16504165 — intervention group
Group type: COMPARATOR
Intervention: Usual care based on a pain contingent basis
Number of subjects: 126
Study 12628866 — intervention group
Group type: EXPERIMENTAL
Intervention: Somnosmart (Weinmann; Hamburg, Germany)
Number of subjects: 16
Study 12628866 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoset (Resmed; North Ryde, Australia)
Number of subjects: 16
Study 12628866 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both devices
Number of subjects: 16
Study 10960046 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of GTN (0.5 microg/kg per minute for 20 min)
Number of subjects: 16
Study 10960046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10960046 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of GTN
Number of subjects: 16
Study 10960046 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n=16)
Number of subjects: 16
Study 9108851 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron therapy
Number of subjects: 67
Study 9108851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 1288902 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl, 2.5 micrograms.kg‐1
Number of subjects: 29
Study 1288902 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl, 5 micrograms.kg‐1
Number of subjects: 29
Study 1288902 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl, 10 micrograms.kg‐1
Number of subjects: 29
Study 1288902 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 29
Study 3876031 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g every four hours)
Number of subjects: 100
Study 3876031 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (2 g intravenously)
Number of subjects: 100
Study 3876031 — intervention group
Group type: COMPARATOR
Intervention: Antacids (every two hours)
Number of subjects: 100
Study 3876031 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (50 mg intravenously daily)
Number of subjects: 100
Study 29091470 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated chewing gum (200 mg caffeine)
Number of subjects: 18
Study 29091470 — intervention group
Group type: COMPARATOR
Intervention: Placebo (noncaffeinated chewing gum)
Number of subjects: 18
Study 29091470 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated chewing gum (200 mg caffeine) in low habitual caffeine consumers (<40 mg/day)
Number of subjects: 18
Study 29091470 — intervention group
Group type: COMPARATOR
Intervention: Placebo (noncaffeinated chewing gum) in low habitual caffeine consumers (<40 mg/day)
Number of subjects: 18
Study 29091470 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated chewing gum (200 mg caffeine) in moderate/high habitual caffeine consumers (>130 mg/day)
Number of subjects: 18
Study 29091470 — intervention group
Group type: COMPARATOR
Intervention: Placebo (noncaffeinated chewing gum) in moderate/high habitual caffeine consumers (>130 mg/day)
Number of subjects: 18
Study 27046296 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Number of subjects: 90
Study 27046296 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (looking at their paretic limb)
Number of subjects: 90
Study 27046296 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (mirror therapy and comparison)
Number of subjects: 90
Study 27046296 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (per protocol analyses)
Number of subjects: 90
Study 24725910 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision making intervention
Number of subjects: 58
Study 24725910 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 58
Study 23790113 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-cell stents
Number of subjects: 96
Study 23790113 — intervention group
Group type: COMPARATOR
Intervention: Open-cell stents
Number of subjects: 96
Study 23790113 — intervention group
Group type: EXPERIMENTAL
Intervention: Both stent types
Number of subjects: 96
Study 23790113 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic patient group
Number of subjects: 96
Study 20798909 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based care
Number of subjects: 240
Study 20798909 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240
Study 19096961 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month stay at a wellness centre focusing on diet, exercise and stress management
Number of subjects: 200
Study 19096961 — intervention group
Group type: COMPARATOR
Intervention: 30-60 min of oral and written information on lifestyle intervention
Number of subjects: 200
Study 15826846 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency rTMS (17 Hz)
Number of subjects: 71
Study 15826846 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency rTMS (1 Hz)
Number of subjects: 71
Study 15826846 — intervention group
Group type: COMPARATOR
Intervention: Placebo rTMS
Number of subjects: 71
Study 14737792 — intervention group
Group type: EXPERIMENTAL
Intervention: Tokusou Rebase Fast Set
Number of subjects: 10
Study 14737792 — intervention group
Group type: EXPERIMENTAL
Intervention: Coe Kooliner
Number of subjects: 10
Study 14737792 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Hard
Number of subjects: 10
Study 14737792 — intervention group
Group type: COMPARATOR
Intervention: All materials
Number of subjects: 10
Study 10758049 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance coronary angiography (MRCA)
Number of subjects: 25
Study 10758049 — intervention group
Group type: COMPARATOR
Intervention: X-ray coronary angiography
Number of subjects: 25
Study 10758049 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MRCA and x-ray coronary angiography
Number of subjects: 25
Study 8820204 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained to plan, write, and revise opinion essays; used interactive dialogues for planning and revising.
Number of subjects: 38
Study 8820204 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained participants
Number of subjects: 38
Study 8820204 — intervention group
Group type: COMPARATOR
Intervention: Untrained control group
Number of subjects: 38
Study 1601688 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonprescription firm-support pantyhose
Number of subjects: 30
Study 1601688 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonprescription sheer-support pantyhose
Number of subjects: 30
Study 1601688 — intervention group
Group type: COMPARATOR
Intervention: Follow-up after one year
Number of subjects: 30
Study 4015326 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine hydrochloride
Number of subjects: 20
Study 4015326 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride
Number of subjects: 20
Study 4015326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30871921 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine + ACEI/ARB
Number of subjects: 0
Study 30871921 — intervention group
Group type: COMPARATOR
Intervention: Placebo + ACEI/ARB
Number of subjects: 0
Study 28528818 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar tendon vibration
Number of subjects: 27
Study 28528818 — intervention group
Group type: COMPARATOR
Intervention: Control condition (vibrator turned off)
Number of subjects: 27
Study 28528818 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve stimulation (2×motor threshold)
Number of subjects: 27
Study 28528818 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-vibration recovery
Number of subjects: 27
Study 25725502 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunlight intervention trial
Number of subjects: 31
Study 23519576 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg
Number of subjects: 40
Study 23519576 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 600 mg
Number of subjects: 40
Study 23519576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23519576 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 40
Study 21677639 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 16
Study 21677639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 19388994 — intervention group
Group type: EXPERIMENTAL
Intervention: Serous-lined extramural tunnel
Number of subjects: 60
Study 19388994 — intervention group
Group type: COMPARATOR
Intervention: T-limb ileal procedure
Number of subjects: 60
Study 16430561 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 12 mg
Number of subjects: 90
Study 16430561 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 17 mg
Number of subjects: 90
Study 16430561 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 90
Study 15262911 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive subjects
Number of subjects: 13
Study 11773294 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate and fluorouracil (MF)
Number of subjects: 0
Study 11773294 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and methotrexate (CMF)
Number of subjects: 0
Study 11773294 — intervention group
Group type: COMPARATOR
Intervention: CMF plus placebo, CMF plus tamoxifen (TAM), doxorubicin and cyclophosphamide (AC) plus placebo, AC plus TAM
Number of subjects: 0
Study 11773294 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM)
Number of subjects: 0
Study 11773294 — intervention group
Group type: EXPERIMENTAL
Intervention: TAM plus either MF or CMF
Number of subjects: 0
Study 11773294 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery and chemotherapy
Number of subjects: 0
Study 11773294 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus TAM
Number of subjects: 0
Study 11773294 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy (XRT)
Number of subjects: 0
Study 11773294 — intervention group
Group type: EXPERIMENTAL
Intervention: XRT + TAM
Number of subjects: 0
Study 9564793 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TAA) 400 microg twice daily
Number of subjects: 121
Study 9564793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 7752836 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of Coenzyme Q10 (CoQ10) once a week for 6 weeks
Number of subjects: 10
Study 7752836 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil (control)
Number of subjects: 10
Study 3357071 — intervention group
Group type: EXPERIMENTAL
Intervention: VT‐1 (no uncertainty, prescribed therapy)
Number of subjects: 304
Study 3357071 — intervention group
Group type: EXPERIMENTAL
Intervention: VT‐2 (no uncertainty, prescribed therapy)
Number of subjects: 304
Study 3357071 — intervention group
Group type: EXPERIMENTAL
Intervention: VT‐3 (expressed uncertainty, prescribed antibiotics without resolution)
Number of subjects: 304
Study 3357071 — intervention group
Group type: EXPERIMENTAL
Intervention: VT‐4 (expressed uncertainty, consulted reference book, then prescribed)
Number of subjects: 304
Study 3357071 — intervention group
Group type: EXPERIMENTAL
Intervention: VT‐5 (expressed uncertainty, checked computer, then prescribed)
Number of subjects: 304
Study 31332977 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily vacuuming of mattresses for 2 weeks
Number of subjects: 40
Study 31332977 — intervention group
Group type: COMPARATOR
Intervention: Control group (cleaned rooms without vacuuming mattresses)
Number of subjects: 40
Study 29132336 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhang's dynamic guideline for labor progression
Number of subjects: 6582
Study 29132336 — intervention group
Group type: COMPARATOR
Intervention: 4-h action line guideline for labor progression
Number of subjects: 6582
Study 25636601 — intervention group
Group type: EXPERIMENTAL
Intervention: P/T[-] beverage (amino acid beverage deficient in phenylalanine and tyrosine)
Number of subjects: 16
Study 25636601 — intervention group
Group type: EXPERIMENTAL
Intervention: P/T[-] beverage
Number of subjects: 16
Study 23743404 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapropterin (10 mg/kg)
Number of subjects: 9
Study 23743404 — intervention group
Group type: COMPARATOR
Intervention: Local BH4 administration
Number of subjects: 9
Study 23743404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 21508092 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C and vitamin E supplementation (n = 14)
Number of subjects: 28
Study 21508092 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 14)
Number of subjects: 28
Study 19455068 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 135
Study 19455068 — intervention group
Group type: COMPARATOR
Intervention: Letrozole
Number of subjects: 135
Study 19455068 — intervention group
Group type: EXPERIMENTAL
Intervention: Diary and event button measures
Number of subjects: 135
Study 16364159 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 500 microg once daily
Number of subjects: 499
Study 16364159 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP) 200 microg twice daily (400 microg/day)
Number of subjects: 499
Study 15243285 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17beta‐estradiol (50 microg/day) and nomegestrol (5 mg/day for 12 days/month)
Number of subjects: 44
Study 15243285 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 44
Study 15243285 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17beta‐estradiol and nomegestrol (HT)
Number of subjects: 44
Study 10654500 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (20 mg four times daily)
Number of subjects: 167
Study 10654500 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol + Magnesium (18 g over 24 hours)
Number of subjects: 167
Study 9059558 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human GH (rhGH) 12 IU/day s.c. for 7 days, followed by salmon calcitonin (sCT) 50 IU/day s.c. for 21 days
Number of subjects: 30
Study 9059558 — intervention group
Group type: COMPARATOR
Intervention: placebo for 7 days, followed by salmon calcitonin (sCT) for 21 days
Number of subjects: 30
Study 9059558 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human GH (rhGH) for 7 days, followed by placebo for 21 days
Number of subjects: 30
Study 8356371 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ketoprofen controlled release (morning dose)
Number of subjects: 163
Study 8356371 — intervention group
Group type: COMPARATOR
Intervention: 200 mg ketoprofen controlled release (evening dose)
Number of subjects: 163
Study 8356371 — intervention group
Group type: EXPERIMENTAL
Intervention: Both morning and evening doses of ketoprofen
Number of subjects: 163
Study 3301990 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard reminder
Number of subjects: 540
Study 3301990 — intervention group
Group type: COMPARATOR
Intervention: Control group (no postcard reminder)
Number of subjects: 540
Study 3301990 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic visit during autumn months
Number of subjects: 540
Study 3301990 — intervention group
Group type: EXPERIMENTAL
Intervention: No clinic visit during autumn months
Number of subjects: 540
Study 31948454 — intervention group
Group type: EXPERIMENTAL
Intervention: Jump Start intervention
Number of subjects: 658
Study 31948454 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 658
Study 28833181 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 72
Study 28833181 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdebrider-assisted inferior turbinoplasty
Number of subjects: 72
Study 28833181 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 72
Study 28833181 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment procedures (radiofrequency ablation, microdebrider-assisted inferior turbinoplasty)
Number of subjects: 72
Study 27898428 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low-Calorie Diet (VLCD) for 3 months
Number of subjects: 0
Study 27898428 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight maintenance phase after VLCD
Number of subjects: 0
Study 27898428 — intervention group
Group type: COMPARATOR
Intervention: Lean control group
Number of subjects: 0
Study 24405854 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured education intervention incorporating training in self‐monitoring of blood glucose (SMBG) or urine glucose (SMUG)
Number of subjects: 39
Study 24405854 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for educators
Number of subjects: 39
Study 24405854 — intervention group
Group type: EXPERIMENTAL
Intervention: Commitment to unbiased delivery
Number of subjects: 39
Study 22543555 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognitive and perceptive rehabilitation treatment (TG)
Number of subjects: 14
Study 22543555 — intervention group
Group type: COMPARATOR
Intervention: Common physical therapy (CG)
Number of subjects: 14
Study 20861328 — intervention group
Group type: EXPERIMENTAL
Intervention: Mtb72F/AS02(A) (10 μg antigen)
Number of subjects: 50
Study 20861328 — intervention group
Group type: EXPERIMENTAL
Intervention: Mtb72F/AS02(A) (40 μg antigen)
Number of subjects: 50
Study 20861328 — intervention group
Group type: EXPERIMENTAL
Intervention: Mtb72F/AS02(A) (10 or 40 μg antigen)
Number of subjects: 50
Study 20861328 — intervention group
Group type: EXPERIMENTAL
Intervention: Mtb72F/AS02(A)
Number of subjects: 50
Study 20861328 — intervention group
Group type: COMPARATOR
Intervention: AS02(A) alone
Number of subjects: 50
Study 18384663 — intervention group
Group type: EXPERIMENTAL
Intervention: 20‐mg rabeprazole once daily for 4 weeks
Number of subjects: 40
Study 18384663 — intervention group
Group type: EXPERIMENTAL
Intervention: 20‐mg rabeprazole once daily for 8 weeks
Number of subjects: 40
Study 18384663 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 40
Study 18384663 — intervention group
Group type: COMPARATOR
Intervention: Erosive oesophagitis (EO) patients
Number of subjects: 40
Study 16500951 — intervention group
Group type: EXPERIMENTAL
Intervention: BiPAP ventilation
Number of subjects: 20
Study 16500951 — intervention group
Group type: COMPARATOR
Intervention: IPPV with or without PEEP
Number of subjects: 20
Study 15173856 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate (CHO), high monounsaturated fatty acid (MUFA), and high fibre feed
Number of subjects: 20
Study 15173856 — intervention group
Group type: COMPARATOR
Intervention: Standard composition feeds
Number of subjects: 20
Study 10786750 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (4 mmol)
Number of subjects: 30
Study 10786750 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study 9157585 — intervention group
Group type: EXPERIMENTAL
Intervention: r-VIII SQ
Number of subjects: 36
Study 8363291 — intervention group
Group type: EXPERIMENTAL
Intervention: 200mg of caffeine
Number of subjects: 14
Study 8363291 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5mg of timolol (2.5mL of timolol 0.5% ophthalmic solution)
Number of subjects: 14
Study 8363291 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of caffeine and timolol
Number of subjects: 14
Study 8363291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8363291 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist rest
Number of subjects: 14
Study 3302082 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse colostomy followed by resection with anastomosis (Group T)
Number of subjects: 55
Study 3302082 — intervention group
Group type: COMPARATOR
Intervention: Immediate resection with end colostomy and mucous fistula (Group R)
Number of subjects: 55
Study 30982378 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily plus MTX
Number of subjects: 0
Study 30982378 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab 40 mg every 2 weeks plus MTX
Number of subjects: 0
Study 28280092 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide monotherapy (n = 29)
Number of subjects: 99
Study 28280092 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide in combination with endocrine therapies (n = 70)
Number of subjects: 99
Study 28280092 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane 50 mg/day given with enzalutamide
Number of subjects: 99
Study 28280092 — intervention group
Group type: COMPARATOR
Intervention: Exemestane 25 mg/day
Number of subjects: 99
Study 25577502 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 19
Study 23633399 — intervention group
Group type: EXPERIMENTAL
Intervention: chronoFLO4
Number of subjects: 543
Study 23633399 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX2
Number of subjects: 543
Study 21107891 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke alarms present
Number of subjects: 779
Study 21107891 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional smoke alarms
Number of subjects: 779
Study 21107891 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance with functionality and placement recommendations
Number of subjects: 779
Study 21107891 — intervention group
Group type: EXPERIMENTAL
Intervention: Post‐1980 constructions
Number of subjects: 779
Study 19167725 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifting to urinate without a password
Number of subjects: 570
Study 19167725 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 570